Concentration of anti-pneumococcal capsular polysaccharide IgM, IgG and IgA specific antibodies in adult blood donors

Parker, Antony R.; Allen, Syreeta; Harding, Stephen

doi:10.1016/j.plabm.2016.02.004

Cited by 16 publications

(32 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[3][4][5] The IgA and IgM responses to pneumococcal vaccination have been reported to be compromised in some pediatric patients with antibody deficiencies [6] and correlates with common variable immunodeficiency (CVID) patients and their history of infection. [7] Using reported unknown vaccination reference ranges [8] we measured the concentrations of Pneumococcal IgA and IgM responses to Pneumovax in individuals diagnosed with antibody deficiencies who had normal and abnormal pneumococcal capsular polysaccharide (PCP) IgG concentrations.…”

Section: Introductionmentioning

confidence: 99%

Concentrations of Pneumococcal IgA and IgM are compromised in some individuals with antibody deficiencies

Carlos

Torre

Carús

et al. 2017

Journal of Immunoassay and Immunochemistry

Self Cite

View full text Add to dashboard Cite

The response to pneumococcal vaccination is assessed by measurement of antigen specific IgG only and is compromised in a number of antibody deficiencies. We measured the concentrations of Pneumococcal IgA and IgM in individuals with both normal and abnormal pneumococcal capsular polysaccharide (PCP) IgG concentrations. A higher number of individuals had abnormal pre-vaccination IgA and IgM concentrations below the lower limit of the normal range compared to the control group. Post vaccination a lower number of individuals had IgA and IgM concentrations below the upper limit of the normal range compared to the control group. Non responders had a higher percentage of individuals with a prior history of infection. In addition, individuals with a history of prior infection had lower pre- and post-vaccination concentrations of PCP IgG, IgA, and IgM. Post-vaccination IgA and IgM concentrations identified four groups of responses which correlated with prior history of infection. A higher percentage of individuals with abnormal PCP IgA and IgM concentrations had a history of prior infection compared to the percentage of individuals with normal concentrations. In individuals with an antibody deficiency, measurement of Pneumococcal IgA and IgM correlates with the number of individuals with prior history of infection.

show abstract

Section: Introductionmentioning

confidence: 99%

Concentrations of Pneumococcal IgA and IgM are compromised in some individuals with antibody deficiencies

Carlos

Torre

Carús

et al. 2017

Journal of Immunoassay and Immunochemistry

Self Cite

View full text Add to dashboard Cite

show abstract

“…Twelve patients (60%) had significant IgG antibody concentration, 15 patients (75%) had IgG2, 12 patients (60%) had IgM, and 5 patients (25%) had IgA. The threshold antibody level correlated with a protection from invasive disease is available in Rose et al for IgG and IgG2 and Parker et al for IgA and IgM: 51.5 µg/mL IgG, 19.5 µg/mL IgG2, l50 UI/mL IgA, and 20 U/mL IgM, respectively.…”

Section: Resultsmentioning

confidence: 99%

“…To determine responders and nonresponders, immunoglobulin subtypes concentrations were compared to published isotype-specific antibody concentration. 11,12 3 | RESULTS…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Response to pneumococcal vaccination in multiple myeloma

et al. 2019

Self Cite

View full text Add to dashboard Cite

Background Streptococcus pneumoniae infection causes morbidity and mortality in multiple myeloma patients. Pneumococcal vaccination is commonly given to immunocompromised myeloma patients; however response data are sparse. Here, we present longitudinal response data to pneumococcal vaccination in multiple myeloma patients. Method Twenty‐eight multiple myeloma patients were included, 25 of whom were newly diagnosed. All the patients received two vaccines Prevnar13® and Pneumo23®. Serotype‐specific IgG was measured by ELISA for all 23 vaccine serotypes at baseline, and then sequentially at different time points postvaccination until treatment ended. Response to vaccination is available for 20 patients. The primary endpoint was the incidence rate of patients who obtained an isotype response serum concentration after vaccination. Secondary endpoints included detailed isotype increase, time to first increase, further assessment of a decreased anti‐pneumococcal serum concentrations following treatment including autologous stem cell transplantation (ASCT), rate of infection with a special attention to pneumococcal infection. Results The median age was 66 years and the male to female ratio was 0.6. Anti‐pneumococcal capsular polysaccharide (anti‐PCP23) IgG, IgG2, IgA, and IgM responses were detected within 1 week postvaccination. Response to at least one subtype of antibody was obtained in 85% (n = 17) of patients, for at least two subtypes in 65% (n = 13), for at least three subtypes in 55% (n = 11), and 2 patients responded to all four subtypes. The median increase in the concentration of anti‐PCP23 isotypes was threefold following vaccination, with the highest increase observed when Pneumo23® was given more than 30 days after Prevnar13®. The anti‐pneumococcal geometric mean concentration decreased significantly for all subtypes over time independently of treatment approaches. Conclusion Myeloma has the ability to demonstrate a response to pneumococcal vaccine, independently of preexisting hypogammaglobulinemia and possibly of treatment‐induced immunodepression. We also observed a drop in the serum response overtime and following autologous transplantation. Further studies in larger sample are needed to understand the benefit of vaccination strategies in these patients.

show abstract

“…[14] Adult blood donor samples (n = 79, median age 55 years, range 18-90 years) were collected in donor centres by Biomex Solutions (Heidelberg, Germany) and purchased from Quest Biomedical (Solihull, UK). [15] (2) Control Group B consisted of matched pre and post-vaccination samples from healthy adults vaccinated with Pneumovax (n = 10, 20 samples [16] ). For control group B, post vaccination samples were taken 28 days post vaccination (16) and for patient groups A-C samples were taken during routine immunological investigation 3-8 weeks post vaccination.…”

Section: Description Of Clinical Samplesmentioning

confidence: 99%

Measurement of the IgG2 response to Pneumococcal capsular polysaccharides may identify an antibody deficiency in individuals referred for immunological investigation

Parker¹,

Ventura

Sims³

et al. 2017

Journal of Immunoassay and Immunochemistry

Self Cite

View full text Add to dashboard Cite

IgG2 is the most efficient subclass for providing protection against pneumococcal pathogens. We hypothesised that some individuals may be unable to mount an effective pneumococcal capsular polysaccharide (PCP) IgG2 response despite having a normal PCP IgG concentration (PCP IgG2 deficient). The median pre-vaccination PCP IgG2 concentration was significantly lower in individuals referred for immunological investigation compared to healthy controls (2.8 mg/L range, 95% CI 1.1-88 vs. 29.5mg/L, 95% CI 13.5-90, p = 0.0002). PCP IgG:IgG2 ratios were significantly higher for the referral population than for healthy controls suggesting the increased production of PCP specific subclasses other than IgG2. The percentage of individuals with PCP IgG2 deficiency was significantly higher in referral groups compared to controls (31% vs. 5%; p = 0.0009) and in an individual with PCP IgG2 deficiency, the balance of PCP specific IgG subclass antibodies post vaccination changed from IgG2>IgG1>IgG3>IgG4 to IgG1>IgG3>IgG2>IgG4. The median PCP IgG2 concentration in those with PCP IgG2 deficiency was significantly lower in the referral groups compared to controls (7.8 mg/L, 95% CI 1.1-12 vs. 12.7 mg/L, 95% CI 11.8-13.1; p = 0.006). The data suggests a defect in the production PCP IgG2 may be present in individuals with normal PCP IgG referred for immunological investigation.

show abstract

Concentration of anti-pneumococcal capsular polysaccharide IgM, IgG and IgA specific antibodies in adult blood donors

Cited by 16 publications

References 9 publications

Concentrations of Pneumococcal IgA and IgM are compromised in some individuals with antibody deficiencies

Concentrations of Pneumococcal IgA and IgM are compromised in some individuals with antibody deficiencies

Response to pneumococcal vaccination in multiple myeloma

Measurement of the IgG2 response to Pneumococcal capsular polysaccharides may identify an antibody deficiency in individuals referred for immunological investigation

Contact Info

Product

Resources

About